Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of the Introduction of mTor Inhibitors in the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response to Control Viral Replication in Kidney Transplant Patients

NCT04936971 is registered in ClinicalTrials.gov with Edoardo Melilli as lead sponsor.

NCT NCT04936971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04936971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of the Introduction of mTor Inhibitors in the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response to Control Viral Replication in Kidney Transplant Patients
Lead sponsor
Edoardo Melilli
Phase
Phase 4
Overall status
Withdrawn
Start date
September 30, 2021
Completion date
September 30, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infections, kidney transplantation